Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.460
-0.030 (-0.86%)
At close: Aug 7, 2025, 4:00 PM
3.700
+0.240 (6.94%)
Pre-market: Aug 8, 2025, 8:40 AM EDT
Company Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir.
Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Oct 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Jean-Pierre Sommadossi |
Contact Details
Address: 225 Franklin Street, Suite 2100 Boston, Massachusetts 02110 United States | |
| Phone | 857 284 8891 |
| Website | ateapharma.com |
Stock Details
| Ticker Symbol | AVIR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 0001593899 |
| CUSIP Number | 04683R106 |
| ISIN Number | US04683R1068 |
| Employer ID | 46-0574869 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Andrea J. Corcoran J.D. | Chief Financial Officer, Executive Vice President of Legal and Secretary |
| John F. Vavricka | Chief Commercial Officer |
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer |
| Wayne Foster CPA | Executive Vice President of Finance and Chief Accounting Officer |
| Jonae R. Barnes | Senior Vice President of Investor Relations and Corporate Communications |
| Adel Moussa Ph.D. | Executive Vice President of Chemistry |
| Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development |
| Keith Pietropaolo | Executive Vice President of Clinical Sciences and Project Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 7, 2025 | 10-Q | Quarterly Report |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |
| Jun 20, 2025 | 8-K | Current Report |
| May 14, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |